10-Q: Ensysce Biosciences Reports Q3 2026 Results, Acquisition Impact

Ensysce Biosciences files its Q3 2026 10-Q, detailing a significant net loss driven by acquired in-process R&D from the Cy Biopharma acquisition, while also highlighting progress in grant funding and ongoing liquidity concerns.

Summary

• Ensysce Biosciences filed its Form 10-Q for the quarterly period ended September 30, 2026.
• The company reported a substantial net loss of $82.1 million for the three months ended September 30, 2026, and $88.2 million for the nine months ended September 30, 2026.
• A significant factor in the net loss was the recognition of $79.9 million in acquired in-process research and development (IPR&D) expense related to the acquisition of Cy Biopharma, Inc. on August 5, 2026.
• Cash and cash equivalents stood at $29.7 million as of September 30, 2026.
• The company continues to face substantial doubt regarding its ability to continue as a going concern, with current cash resources projected to fund operations into the second half of 2027.
• Federal grant funding, specifically the MPAR Grant, provided $2.2 million in the third quarter and $4.3 million year-to-date.
• Research and development expenses increased to $3.2 million for the quarter and $9.0 million year-to-date, partly due to the Cy Biopharma acquisition.
• General and administrative expenses were $1.6 million for the quarter and $4.0 million year-to-date.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, substantial acquired in-process R&D expenses, and ongoing concerns about the ability to continue as a going concern, despite progress in acquisitions and grant funding.

Positives

• The acquisition of Cy Biopharma, Inc. on August 5, 2026, has been completed, bringing CY200, a clinical-stage psilocybin-predominant botanical extract for chronic pain, into the company's pipeline.
• The company received $2.2 million in federal grant funding for the third quarter of 2026, an increase from $0.5 million in the prior year's quarter, and $4.3 million year-to-date.
• The company completed a PIPE financing transaction on August 5, 2026, raising approximately $21.5 million in gross proceeds.
• Cash and cash equivalents increased significantly to $29.7 million as of September 30, 2026, from $4.3 million at December 31, 2025, largely due to financing activities.

Negatives

• The company reported a net loss of $82.1 million for the three months ended September 30, 2026, and $88.2 million for the nine months ended September 30, 2026.
• A substantial expense of $79.9 million was recognized for acquired in-process research and development related to the Cy Biopharma acquisition.
• The company's ability to continue as a going concern is subject to substantial doubt, with current cash resources expected to last into the second half of 2027.
• Research and development expenses increased by $2.2 million for the nine months ended September 30, 2026, compared to the prior year, driven by increased clinical activity and the Cy acquisition.
• The company has not generated any product revenue and does not expect to do so in the near future, if at all.
• The company's common stock is at risk of delisting from Nasdaq if it cannot maintain compliance with applicable listing standards.

Risks

• The risk that common stock will be delisted from Nasdaq if compliance with listing standards is not maintained.
• The risk that product candidates PF614 and PF614-MPAR may not be successful in limiting abuse, overdose, or misuse, or providing additional safety upon commercialization.
• The need for substantial additional funding to complete development and commercialization of product candidates.
• The risk that clinical trials may fail to replicate positive results from earlier studies or fail to receive required regulatory approvals.
• The risk that the company may fail to realize the anticipated benefits of the merger with Cy Biopharma.
• The dilutive effect of recent financing transactions may negatively affect the stock price.
• The risk that third parties relied upon for critical services may fail to perform satisfactorily.
• The risk that the company will be unable to obtain and maintain sufficient intellectual property protection or will infringe upon the intellectual property of others.

Future Outlook

The company anticipates continued substantial expenses and net losses for the foreseeable future. Future funding requirements will depend on research and development progress, clinical trial outcomes, regulatory approvals, and the ability to secure additional capital through equity or debt financings, or collaborations. The company expects to fund operations through public or private equity or debt offerings, or other sources.

Management Comments

• Management states that the company has not generated any product revenue and may never be able to develop or commercialize a marketable product.
• Management expects to continue incurring net losses for the foreseeable future and anticipates that expenses and capital requirements will increase substantially.
• Management believes that without additional capital raised through financing transactions, existing cash resources are sufficient to fund current planned operations into the second half of 2027, raising substantial doubt about the ability to continue as a going concern.
• Management expects future general and administrative expenses to approximate current levels.

Industry Context

StockSavvy.ai notes that Ensysce Biosciences operates in the highly competitive and capital-intensive biotechnology sector. The significant net loss and ongoing concern about going concern status are common challenges for clinical-stage companies. The acquisition of Cy Biopharma and the focus on neuroplastogenic therapies for chronic pain, including CRPS, align with emerging trends in pain management and mental health treatments.

Comparison to Industry Standards

• Many clinical-stage biotechnology companies face similar challenges with significant R&D expenses, long development timelines, and the need for substantial capital raises, often resulting in net losses and going concern considerations.
• The valuation of acquired in-process R&D, as seen with the Cy Biopharma acquisition, is a common practice in the industry when acquiring companies with promising but unproven drug candidates.
• The reliance on federal grants, such as the MPAR Grant from NIH/NIDA, is a typical funding source for early-stage research in the U.S. biotechnology landscape.

Legal Proceedings

• No pending legal proceedings against the Company are expected to have a material adverse effect on cash flows, financial condition, or results of operations as of September 30, 2026, and December 31, 2025.

Related Party Transactions

• In connection with the Cy Acquisition, the Company issued 154,821 shares of Series C Preferred Stock to an affiliate of James Morrison, who was appointed President and a member of the Company's Board of Directors, as part of the purchase consideration.

Stakeholder Impact

• Shareholders may experience dilution due to ongoing financing activities and potential future equity issuances.
• The company's ability to continue as a going concern poses a significant risk to all stakeholders, including shareholders, creditors, and employees.
• The potential delisting from Nasdaq could negatively impact share liquidity and investor confidence.

Next Steps

• Provide further information to the MHRA to support protocol CYBIO 001 for the Phase 2a study of CY200.
• Continue advancing the development of CY200, PF614, PF614-MPAR, and other product candidates.
• Seek additional capital through equity or debt financings or collaborations to fund future operations and development activities.
• Monitor compliance with Nasdaq listing standards to avoid delisting.

Key Dates

Recommendation

The company's significant net losses, ongoing going concern issues, and the substantial expense from the Cy acquisition weigh heavily. However, the acquisition itself and the progress in grant funding and financing provide some positive momentum. The path to commercialization remains long and uncertain, making it a speculative investment. A 'hold' recommendation reflects the balance between high risk and potential future upside if development milestones are met and financing is secured.

Keywords

biotechnology, drug development, clinical trials, acquisition, Cy Biopharma, Series C Preferred Stock, net loss, going concern